$LRMR
Larimar Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093733 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.345M $4.917M
YoY Change 15.87% 31.3%
% of Gross Profit
Research & Development $13.92M $19.68M
YoY Change 111.37% 235.01%
% of Gross Profit
Depreciation & Amortization $74.00K $87.00K
YoY Change -7.5% 14.47%
% of Gross Profit
Operating Expenses $18.26M $24.60M
YoY Change 76.65% 155.71%
Operating Profit -$18.26M -$24.60M
YoY Change 76.65% 155.71%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.765M $2.972M
YoY Change 116.86% 137.0%
Pretax Income -$15.50M -$21.63M
YoY Change 71.07% 158.51%
Income Tax
% Of Pretax Income
Net Earnings -$15.50M -$21.63M
YoY Change 71.0% 158.51%
Net Earnings / Revenue
Basic Earnings Per Share -$0.24 -$0.34
Diluted Earnings Per Share -$0.24 -$0.34
COMMON SHARES
Basic Shares Outstanding 63.81M 63.80M
Diluted Shares Outstanding 63.81M 63.80M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $203.7M $226.1M
YoY Change 113.1% 116.95%
Cash & Equivalents $35.07M $32.31M
Short-Term Investments $168.6M $193.8M
Other Short-Term Assets $8.606M $4.315M
YoY Change 196.76% 89.42%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $213.3M $231.1M
YoY Change 116.55% 117.07%
LONG-TERM ASSETS
Property, Plant & Equipment $779.0K $844.0K
YoY Change 29.62% 24.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $621.0K $636.0K
YoY Change -2.05% -1.24%
Total Long-Term Assets $5.765M $6.032M
YoY Change 5.35% 15.16%
TOTAL ASSETS
Total Short-Term Assets $213.3M $231.1M
Total Long-Term Assets $5.765M $6.032M
Total Assets $219.0M $237.2M
YoY Change 110.69% 112.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.686M $2.917M
YoY Change 123.02% 24.45%
Accrued Expenses $13.57M $17.25M
YoY Change 166.45% 295.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.29M $21.16M
YoY Change 148.32% 190.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.336M $4.603M
YoY Change -7.74% 2.04%
Total Long-Term Liabilities $4.336M $4.603M
YoY Change -7.74% 2.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.29M $21.16M
Total Long-Term Liabilities $4.336M $4.603M
Total Liabilities $20.62M $25.76M
YoY Change 83.46% 118.55%
SHAREHOLDERS EQUITY
Retained Earnings -$240.3M -$224.8M
YoY Change 36.85% 35.02%
Common Stock $438.4M $436.4M
YoY Change 63.41% 63.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $198.4M $211.4M
YoY Change
Total Liabilities & Shareholders Equity $219.0M $237.2M
YoY Change 110.69% 112.29%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$15.50M -$21.63M
YoY Change 71.0% 158.51%
Depreciation, Depletion And Amortization $74.00K $87.00K
YoY Change -7.5% 14.47%
Cash From Operating Activities -$24.55M -$13.99M
YoY Change 166.8% 89.93%
INVESTING ACTIVITIES
Capital Expenditures $62.00K $274.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $27.33M -$63.22M
YoY Change -158.87% 542.59%
Cash From Investing Activities $27.27M -$63.49M
YoY Change -158.74% 545.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K -334.0K
YoY Change 0.0%
NET CHANGE
Cash From Operating Activities -24.55M -13.99M
Cash From Investing Activities 27.27M -63.49M
Cash From Financing Activities 30.00K -334.0K
Net Change In Cash 2.756M -77.81M
YoY Change -104.96% 352.33%
FREE CASH FLOW
Cash From Operating Activities -$24.55M -$13.99M
Capital Expenditures $62.00K $274.0K
Free Cash Flow -$24.61M -$14.26M
YoY Change 167.48% 93.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001374690
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36510
dei Entity Registrant Name
EntityRegistrantName
LARIMAR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3857670
dei Entity Address Address Line1
EntityAddressAddressLine1
Three Bala Plaza East
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 506
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19004
dei Entity Address City Or Town
EntityAddressCityOrTown
Bala Cynwyd
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
511-9056
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LRMR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
63806628
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32311000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26749000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
193753000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
60041000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5066000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3385000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
231130000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
90175000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
844000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
684000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3213000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3078000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1339000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
636000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
659000
CY2024Q2 us-gaap Assets
Assets
237162000
CY2023Q4 us-gaap Assets
Assets
95935000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2917000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1283000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17246000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7386000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
992000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
837000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21155000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9506000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4603000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4709000
CY2024Q2 us-gaap Liabilities
Liabilities
25758000
CY2023Q4 us-gaap Liabilities
Liabilities
14215000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63802517
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63802517
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43909069
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43909069
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
64000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
436325000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
270150000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224835000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188554000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-150000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
81000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
211404000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
81720000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
237162000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95935000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19682000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5875000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32621000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10437000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4917000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3745000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8712000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6820000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
24599000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9620000
us-gaap Operating Expenses
OperatingExpenses
41333000
us-gaap Operating Expenses
OperatingExpenses
17257000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24599000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9620000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41333000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17257000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2972000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1254000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5052000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2365000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21627000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8366000
us-gaap Net Income Loss
NetIncomeLoss
-36281000
us-gaap Net Income Loss
NetIncomeLoss
-14892000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63801792
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
63801792
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43897603
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43897603
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58677749
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58677749
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43897603
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43897603
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21627000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8366000
us-gaap Net Income Loss
NetIncomeLoss
-36281000
us-gaap Net Income Loss
NetIncomeLoss
-14892000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-125000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-231000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
43000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-125000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-231000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
43000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21752000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8354000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36512000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14849000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
81720000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161756000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2128000
CY2024Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-106000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-14654000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
230844000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2301000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2024Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-125000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21627000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
211404000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
110903000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1833000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
31000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6526000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
106241000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2043000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
12000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8366000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
99930000
us-gaap Profit Loss
ProfitLoss
-36281000
us-gaap Profit Loss
ProfitLoss
-14892000
us-gaap Share Based Compensation
ShareBasedCompensation
4429000
us-gaap Share Based Compensation
ShareBasedCompensation
3876000
lrmr Cash And Non Cash Operating Lease Expense
CashAndNonCashOperatingLeaseExpense
-86000
lrmr Cash And Non Cash Operating Lease Expense
CashAndNonCashOperatingLeaseExpense
-51000
us-gaap Depreciation
Depreciation
167000
us-gaap Depreciation
Depreciation
154000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-2361000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-645000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1681000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-33000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1626000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
658000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9765000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4043000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-23000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24399000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14916000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
274000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
166582000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
9847000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
35000000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
92259000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-131856000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82412000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
161806000
lrmr Proceeds From Stock Options And Warrant Exercises
ProceedsFromStockOptionsAndWarrantExercises
11000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161817000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5562000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
67496000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28088000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28164000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33650000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95660000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
53000
lrmr Offering Costs Included In Accounts Payable And Accrued Expense
OfferingCostsIncludedInAccountsPayableAndAccruedExpense
50000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
465000
us-gaap Net Income Loss
NetIncomeLoss
-36300000
us-gaap Net Income Loss
NetIncomeLoss
-14900000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224800000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
226100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p>
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
27476000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
193753000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
221229000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
24701000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60041000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
84742000
CY2024Q2 us-gaap Interest Receivable
InterestReceivable
800000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
300000
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2024Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
193903000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
150000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
193753000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
59960000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
81000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60041000
CY2024Q2 lrmr Marketable Securities With Remaining Maturities Greater Than Two Years
MarketableSecuritiesWithRemainingMaturitiesGreaterThanTwoYears
0
CY2023Q4 lrmr Marketable Securities With Remaining Maturities Greater Than Two Years
MarketableSecuritiesWithRemainingMaturitiesGreaterThanTwoYears
0
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2024Q2 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
3733000
CY2023Q4 lrmr Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1994000
CY2024Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
751000
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
332000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
273000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
682000
CY2024Q2 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
309000
CY2023Q4 lrmr Other Prepaid Expense And Other Current Assets
OtherPrepaidExpenseAndOtherCurrentAssets
377000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5066000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3385000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2236000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1909000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1392000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1225000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
844000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
684000
CY2024Q2 lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
CY2023Q2 lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
lrmr Depreciation Expense Excluding Leased Assets
DepreciationExpenseExcludingLeasedAssets
100000
CY2024Q2 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
14629000
CY2023Q4 lrmr Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4594000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1538000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2365000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1079000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
427000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17246000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7386000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
63802517
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63802517
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2024Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0415
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M15D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.96
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4273502
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.06
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1962477
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.05
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2856
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
33150
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.39
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6199973
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9800000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2691015
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1800000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6199973
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.77
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9800000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2301000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2042000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4429000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3876000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
761000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1543000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1473000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1267000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1189000
CY2024Q2 lrmr Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
959000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7192000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1597000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5595000

Files In Submission

Name View Source Status
0000950170-24-093733-index-headers.html Edgar Link pending
0000950170-24-093733-index.html Edgar Link pending
0000950170-24-093733.txt Edgar Link pending
0000950170-24-093733-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lrmr-20240630.htm Edgar Link pending
lrmr-20240630.xsd Edgar Link pending
lrmr-ex31_1.htm Edgar Link pending
lrmr-ex31_2.htm Edgar Link pending
lrmr-ex32_1.htm Edgar Link pending
lrmr-ex3_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
lrmr-20240630_htm.xml Edgar Link completed
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable